BioAge Labs announced positive Phase 1 trial results for BGE-102, an oral NLRP3 inhibitor that significantly reduced inflammation markers like hsCRP by over 85% in obese participants. The drug was well tolerated and showed potential as a best-in-class treatment for cardiovascular and retinal diseases. BioAge plans to start Phase 2 trials for cardiovascular risk mid-2026 and a diabetic macular edema trial by mid-2027, aiming to confirm efficacy and safety in larger patient groups.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
Goldman Sachs reported robust Q2 FY2026 results, with net earnings growing at an annualized rate of 38%. The firm raised $31 billion in private credit and saw a 130% year-over-year surge in equity underwriting revenues, driven by major deals and IPO ...
The Bitwise Bitcoin ETF (BITB) features competitive fees and tight trading spreads comparable to industry leaders like IBIT and FBTC. Despite strong execution on cost and trading efficiency, BITB's market share and asset growth have stalled due to li...
